Endocrine最新文献

{"title":"Oxidative DNA damage and DNA repair gene variants in differentiated thyroid cancer patients treated with radioactive iodine.","authors":"Fevzi Necati Avsar, Semra Doğru Abbasoğlu, Evin Ademoğlu, Tuncay Sahutoglu","doi":"10.1007/s12020-025-04288-7","DOIUrl":"https://doi.org/10.1007/s12020-025-04288-7","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate oxidative DNA damage and its association with polymorphisms in DNA repair enzymes among patients with differentiated thyroid cancer (DTC) treated with high-dose radioactive iodine (RAI, ≥100 mCi). Relationships between DNA damage markers, gene variants, and clinical or tumor characteristics were also explored.</p><p><strong>Methods: </strong>Seventy-nine patients with DTC and 59 age and sex matched controls from a Turkish population were included. Urinary 8-hydroxy-2'-deoxyguanosine (8-oxoG), a marker of oxidative DNA damage, was measured by ELISA at baseline, 2 weeks, and 3 months post-RAI. Genotyping for hOGG1 Ser326Cys and APE1 Asp148Glu polymorphisms was performed on leukocyte-derived DNA using real-time PCR and melting curve analysis.</p><p><strong>Results: </strong>Urinary 8-oxoG levels showed a non-significant upward trend over time (p = 0.252). The Cys/Cys genotype of hOGG1 was more frequent in patients than controls (13 vs. 6%, p = 0.54), while the Ser/Cys genotype was significantly less frequent in patients (36.7 vs. 57.6%; OR: 0.46, 95% CI: 0.22-0.94, p = 0.03). Cys allele frequencies were 0.32 in patients and 0.35 in controls. APE1 genotype and allele distributions did not differ significantly between groups. No associations were found between polymorphisms and 8-oxoG levels or clinical features, including DTC subtype, tumor stage, sex, smoking status, or age.</p><p><strong>Conclusion: </strong>This is the first study to jointly evaluate urinary 8-oxoG and hOGG1/APE1 polymorphisms in Turkish DTC patients receiving RAI. No consistent associations were found with oxidative DNA damage or clinical characteristics. Larger studies are needed to validate these findings.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel nonsense mutation of the glucocorticoid receptor gene causing glucocorticoid resistance with infertility.","authors":"Jiangyun Lei, Yue Wang, Ying Song, Chuan Peng, Zhipeng Wu, Yunjie Xiong, Furong He, Ting Luo, Yu Fang, Yong Xu, Wei Huang, Jinbo Hu, Shumin Yang, Qifu Li, Linqiang Ma","doi":"10.1007/s12020-025-04280-1","DOIUrl":"https://doi.org/10.1007/s12020-025-04280-1","url":null,"abstract":"<p><strong>Purpose: </strong>Chrousos syndrome is a rare disease mainly caused by inactivated mutations in the NR3C1 gene, which encodes the human glucocorticoid receptor (GR). We reported a male patient of Chrousos syndrome, who had a novel nonsense mutation (c.1839T > A, p. Tyr613Ter) in NR3C1 and presented with oligospermic and infertility but without other typical clinical manifestation. The aim of this study is to explore the molecular mechanisms that cause the unique clinical manifestations in this patient.</p><p><strong>Methods: </strong>Mutant plasmids were transfected to HEK293T and HeLa cells to evaluate glucocorticoid sensitivity and GR expression. Proteomic and further cellular experiments were used to illustrate the mechanism of GR expression change induced by mutation.</p><p><strong>Results: </strong>The mutation causes the deletion of the ligand-binding region of the GR (GR Y613*). Compared with GR wild type (GR WT), GR Y613* had a decreased affinity with dexamethasone, reduced nuclear translocation and decreased transactivation of the glucocorticoid response gene mouse mammary tumor virus promoter. GR Y613* caused decreased protein but unchanged gene expression. E3 ligase STUB1 was identified to regulate ubiquitin-proteasome degradation of GR Y613*. Compared with other human tissues and cell types, expression of STUB1 in testis and Sertoli cells was low.</p><p><strong>Conclusions: </strong>GR Y613* causes reduced sensitivity to glucocorticoids. STUB1 promotes ubiquitination and degradation of GR Y613*. Low expression of STUB1 in human testis compared with other tissue might cause accumulation of GR Y613*, as a potential explanation of the infertility of Chrousos syndrome.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High prevalence of hyperuricemia and its risk factors in a Chinese cohort of primary hyperparathyroidism patients.","authors":"Runxue Yuan, An Song, Yun Zhang, Yue Sha, Ou Wang, Yan Jiang, Mei Li, Weibo Xia, Xuejun Zeng, Xiaoping Xing","doi":"10.1007/s12020-025-04276-x","DOIUrl":"https://doi.org/10.1007/s12020-025-04276-x","url":null,"abstract":"<p><strong>Purpose: </strong>Primary hyperparathyroidism (PHPT) is characterized by autonomous and excessive parathyroid hormone (PTH) secretion due to parathyroid gland lesions. Patients can be complicated with hyperuricemia (HUA), however, data about HUA in Chinese PHPT patients are lacking. This study aimed to explore the prevalence of HUA, factors influencing serum uric acid (SUA) level and the impacts of parathyroidectomy (PTX).</p><p><strong>Methods: </strong>328 inpatients diagnosed with PHPT were included in total. Clinical data were collected and compared between HUA and non-HUA group. Multivariate linear regression was used to explore the factors affecting preoperative SUA and its variation after PTX. The impacts of SUA on bone mineral density (BMD) under different models were also analyzed.</p><p><strong>Results: </strong>The prevalence of HUA in PHPT patients was nearly 32%. Compared with non-HUA group, HUA group had significantly higher serum calcium (Ca) (2.92 [2.75, 3.26] vs. 2.78 [2.62, 3.03] mmol/L, P < 0.001), while PTH increased without significance. Gender, body mass index, serum Ca, triglycerides and renal function were independently associated with SUA. SUA decreased after PTX (340.00 [291.50, 421.00] vs. 315.00 [270.50, 375.00] μmol/L, P = 0.018), with change of SUA significantly associating with changes in serum Ca and phosphate. Presurgical SUA was positively related with femoral neck, total hip and lumbar spine BMDs after adjusting for confounders.</p><p><strong>Conclusion: </strong>A relatively high proportion of HUA was found in our study. Besides the common risk factors, hypercalcemia may contribute to the increased SUA in PHPT patients, which could be significantly improved by curative PTX. SUA might have a protective effect on bone loss in PHPT patients.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"Radioactive iodine therapy in low-risk pediatric thyroid cancer: universal standard or selective indication?\"","authors":"Gerdi Tuli, Jessica Munarin, Luisa De Sanctis","doi":"10.1007/s12020-025-04284-x","DOIUrl":"https://doi.org/10.1007/s12020-025-04284-x","url":null,"abstract":"<p><p>Radioactive iodine (RAI) treatment in low-risk pediatric patients with differentiated thyroid cancer (DTC) is still debatable. The objective of this study is to evaluate the outcome of treated and untreated patients in pediatric age. The data of all pediatric patients affected by low-risk category DTC according to ATA (American Thyroid Association) during the period 2010-2024 were reviewed. Patients with DTC dimensions > 2 cm and/or lymph node involvement underwent to RAI. In our cohort 7/14 (50%) of subjects were treated with RAI. Cytological categories after FNAB were TIR3b in 2/7 (28.6%) and TIR5 in 5/7 (71.4%) for RAI-treated patients, whereas TIR3b was observed in 6/7 (85.7%) and TIR5 in 1/7 (14.3%) in untreated patients (p = 0.03). T1 stage was assigned in 1/7 (14.3%) of patient treated with RAI, T2 stage was present in the remaining 6/7 (85.7%), whereas T 1 stage was observed in 6/7 (85.7%) and T2 stage in 1/7 (14.3%) of untreated patients (p = 0.007). No difference was observed regarding disease persistence or recurrence between treated and untreated patients. Considering the young age, a case-by-case approach may be reasonable in subjects assigned to the low-risk category, rather than absolute recommendation for all pediatric patients with DTC.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of peripheral neuropathy with dementia in type 2 diabetes: a 5-year follow-up study using the national health insurance service-national health information database.","authors":"Heung Yong Jin, Ko Woon Kim, Kyung Ae Lee, Tae Sun Park, Min Ji Kim, Jong Seung Kim","doi":"10.1007/s12020-025-04227-6","DOIUrl":"https://doi.org/10.1007/s12020-025-04227-6","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether the incidence of dementia is associated with diabetic peripheral neuropathy (DPN) in type 2 diabetes.</p><p><strong>Methods: </strong>Using the National Health Insurance Service-National Health Information Database, we calculated the incidence of various types of dementia according to type 2 diabetes with or without DPN by applying multivariate Cox regression analysis. Propensity score matching was performed to equalize each group by considering demographic characteristics and underlying conditions.</p><p><strong>Results: </strong>The incidence of various types of dementia was higher in patients with type 2 diabetes than in those without diabetes. The risk of developing dementia was higher in type 2 diabetes with DPN than in type 2 diabetes without DPN, irrespective of dementia type (all dementia: 1.53 vs. 2.1 vs. 1.4, P < 0.05, Alzheimer's disease: 1.46 vs. 1.98 vs. 1.34, P < 0.05, vascular dementia: 1.86 vs. 2.75 vs. 1.66, P < 0.05, other dementia: 1.62 vs. 2.19 vs. 1.48, P < 0.05; all type 2 diabetes vs. type 2 diabetes with DPN vs. type 2 diabetes without DPN compared with non-diabetes). When sodium-glucose cotransporter-2 inhibitors (SGLT2Is) were used, the incidence of all dementia types was lower in patients with type 2 diabetes than in patients with type 2 diabetes who did not use SGLT2Is although the incidence showed more decreased trend when dipeptidyl peptidase IV inhibitor (DPPIVI) was combined (all dementia: 0.51-0.71, P < 0.05, Alzheimer's disease: 0.78-0.80, P < 0.05, vascular dementia: 0.28-0.35, P < 0.05, other dementia: 0.2-0.70, P < 0.05; SGLT2Is user vs. neither SGLT2I nor DPPIVI). This pattern was also observed in patients with type 2 diabetes and DPN (all dementia: 0.32-0.56, P < 0.05, Alzheimer's disease: 0.44-0.55, P < 0.05, vascular dementia: 0.33, P < 0.05, other dementia: 0.53, P < 0.05; SGLT2Is user vs. neither SGLT2I nor DPPIVI).</p><p><strong>Conclusions: </strong>More active diagnostic and prevention efforts are needed to address the risk of developing all forms of dementia, including vascular dementia, in patients with diabetes and DPN.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of anti-Müllerian hormone: insights into ovarian reserve, primary ovarian insufficiency, and menopause prediction.","authors":"Eleftheria Karaviti, Dimitra Karaviti, Eleni-Rafaela Kani, Efstathia Chatziandreou, Stavroula A Paschou, Theodora Psaltopoulou, Sophia Kalantaridou, Irene Lambrinoudaki","doi":"10.1007/s12020-025-04265-0","DOIUrl":"https://doi.org/10.1007/s12020-025-04265-0","url":null,"abstract":"<p><p>This review highlights the role of Anti-Müllerian Hormone (AMH) in ovarian insufficiency and as a predictor of menopause. AMH, produced by granulosa cells in growing follicles, is a key marker of ovarian reserve, reflecting the remaining pool of viable follicles. In cases of primary ovarian insufficiency (POI), AMH levels are significantly reduced, aiding in diagnosis and distinguishing POI from other causes of amenorrhea. AMH levels below 8 pmol/L have shown high sensitivity (85%) and specificity (100%) for diagnosing POI in women with secondary oligomenorrhea. Regarding ovarian aging, AMH declines steadily with age, serving as a reliable predictor of menopausal timing. AMH levels are linked to menopausal symptoms, particularly vasomotor symptoms like hot flashes and their severity. However, its reliability for diagnosing menopause is inconsistent, especially in younger populations or when determining the exact onset. AMH levels can predict an earlier onset of menopause with limited sensitivity and specificity, particularly when using age-specific concentrations, as lower age-specific AMH levels are associated with an earlier menopause onset. Tracking AMH over time can improve the prediction of menopause. The accuracy of AMH measurements can be enhanced when considered alongside other hormonal markers or clinical symptoms. In polycystic ovary syndrome (PCOS), elevated AMH levels suggest a delayed onset of menopause, indicating an approximately two-year longer reproductive lifespan compared to women without PCOS (mean menopause age: 51.4 years in PCOS cases vs. 49.7 years in healthy controls). In endometriosis, AMH levels generally decline after surgery; however, they remain stable after chemotherapy, even years later, indicating that the decline in ovarian reserve may not be significantly affected.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human-machine collaborative risk assessment model for thyroid nodules based on local attention and multi-scale feature extraction: a multi-center clinical study.","authors":"Shunlan Liu, Yang Yang, Mingli Cai, Zhirong Xu, Shaozheng He, Qichen Su, Peizhong Liu, Guorong Lyu","doi":"10.1007/s12020-025-04278-9","DOIUrl":"https://doi.org/10.1007/s12020-025-04278-9","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate a human-machine collaborative risk assessment model for thyroid nodules using local attention mechanisms and multi-scale feature extraction and compare its performance with those of radiologists of varying experience levels.</p><p><strong>Methods: </strong>A multi-center diagnostic study was conducted using ultrasound image datasets from six hospitals in China. The model was trained on 8397 images from 8063 patients (training set) and validated on 253 images from 245 patients across multiple centers. The diagnostic performance of the model was compared with those of radiologists with varying levels of experience. An assistive strategy was developed where radiologists adjusted their diagnoses based on model results.</p><p><strong>Results: </strong>The model achieved recognition accuracies of 0.966, 0.809, 0.826, 0.837, and 0.861 for composition, echogenicity, margin, echogenic foci, and orientation, respectively. The area under the receiver operating characteristic curve (AUROC) for the model in diagnosing benign and malignant nodules was 0.882, significantly higher than that of the junior radiologist (0.789; P < 0.0001). The AUROC of the model was between that of the intermediate (0.837) and senior (0.892) radiologists, with no significant difference compared to either group (both P > 0.05). The assistive strategy improved the AUROC for the junior radiologist from 0.789 to 0.859 (P < 0.0001) and increased sensitivity from 66.11% to 80.00% (P < 0.05), with specificity unchanged.</p><p><strong>Conclusion: </strong>The model accurately identified thyroid nodule risk features and enhanced diagnostic performance, particularly for the junior radiologist, improving sensitivity in diagnosing thyroid nodules.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144127020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of serum Mg²⁺ concentration in patients with heart failure and type 2 diabetes mellitus: a retrospective cohort study.","authors":"Yangyang Jiang, Jingshu Zhang, Zhichao Jiang, Xiaoyu Liu, Lixin Wang","doi":"10.1007/s12020-025-04282-z","DOIUrl":"https://doi.org/10.1007/s12020-025-04282-z","url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies have discovered an inverse correlation between serum Mg²⁺ concentration and the risk of developing heart failure (HF) as well as atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM). The prognostic relevance of serum Mg²⁺ concentration in patients with HF and T2DM remains unclear.</p><p><strong>Objectives: </strong>To assess the association of serum Mg²⁺ concentration with cardiovascular event rates in a retrospective cohort of patients with HF and T2DM.</p><p><strong>Methods: </strong>This study included patients diagnosed with HF and T2DM in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, from July 2018 to December 2021. The primary endpoint was cardiovascular death or rehospitalization for HF.</p><p><strong>Results: </strong>This study included 216 patients with HF and T2DM. Patients were divided into three groups (T1 [serum Mg²⁺ level ≤ 0.8 mmol/L], T2 [0.8 < serum Mg²⁺ level ≤ 0.89 mmol/L], T3 [serum Mg²⁺ level ≥ 0.9 mmol/L]) based on serum Mg²⁺ level. The Kaplan-Meier analysis revealed that the incidence rate of primary endpoint was significantly increased among three groups (P < 0.001). In multivariate Cox regression model, elevated serum Mg²⁺ level was considered as a protective factor in the coexistence of T2DM and HF with poor prognosis.</p><p><strong>Conclusions: </strong>Our results indicated that increased serum Mg²⁺ concentration may improve long-term prognosis of patients with HF and T2DM.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between serum uric acid to high density lipoprotein ratio and cardiometabolic-related risk in adults with obesity.","authors":"Luisella Vigna, Patrizia Landi, Melania Gaggini, Filomena Napolitano, Francesca Gori, Alessandra Piontini, Fabrizio Minichilli, Cristina Vassalle","doi":"10.1007/s12020-025-04258-z","DOIUrl":"https://doi.org/10.1007/s12020-025-04258-z","url":null,"abstract":"<p><strong>Introduction: </strong>The uric acid (UA) to high density lipoproteins (HDL) ratio (UHR) has recently emerged as a new effective biomarker for inflammation and cardiometabolic diseases. However, the relationship between UHR and the metabolic syndrome and its components and other cardiometabolic parameters in individuals with obesity remains to be further investigated.</p><p><strong>Aim: </strong>To evaluate UHR levels in participants with obesity, as well correlation of UHR with other cardiometabolic risk factors. Moreover, the predictive value of UHR for insulin resistance, metabolic syndrome and visceral adiposity (estimated by using waist circumference) was evaluated, also with respect to UHR components (UA and HDL alone).</p><p><strong>Methods: </strong>Participants were enrolled from the Center of Obesity and Work, Occupational Health Unit of Clinica del Lavoro \"L. Devoto\", Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (Italy) and divided into two groups according to body mass index (BMI) values; controls (when BMI < 30 kg/m²) and participants with obesity (when BMI ≥ 30 kg/m²).</p><p><strong>Results: </strong>A total of 1743 (1268 females, mean age 52 ± 14 years) was enrolled in the study. Multiple logistic regression analysis indicated a significant association between obesity and UHR (odds ratio (95% confidence intervals) p value; 1.1 (1-1.1) < 0.01) after adjustment for different biomarkers of cardiometabolic risk. The area under the ROC curve (AUC) of UHR was significantly larger compared with the use of HDL or UA alone for insulin resistance (0.73, 0.3 and 0.67, respectively), metabolic syndrome (0.77, 0.26 and 0.69, respectively) and waist circumference (0.65, 0.37 and 0.62, respectively).</p><p><strong>Conclusion: </strong>Elevated UHR, better than UA or HDL alone, demonstrates a significant correlation with obesity and cardiometabolic parameters, so it could be used as a potential indicator of cardiometabolic risk in this clinical setting.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial and temporal distribution and evolutionary trend of thyroid cancer incidence in Guangzhou, 2010-2020.","authors":"Boheng Liang, Jingjing Zhou, Suixiang Wang, Huan Xu, Ke Li, Huiting Liang, Zeyu Sun, Yanhong Liu, Yawen Wang, Jiaqi Zhang, Pengzhe Qin, Xiaoqin Hu","doi":"10.1007/s12020-025-04274-z","DOIUrl":"https://doi.org/10.1007/s12020-025-04274-z","url":null,"abstract":"<p><strong>Purpose: </strong>The spatial and temporal distribution of thyroid cancer in Guangzhou was studied using spatial information system technology, offering a scientific foundation for successful thyroid cancer prevention and treatment.</p><p><strong>Methods: </strong>The Joinpoint model was used to assess the incidence rate of thyroid cancer over time in various regions. Hierarchical maps were created with the ArcGIS software to investigate the spatial distribution features of the incidence rate. Spatial autocorrelation and spatiotemporal scanning analysis methods were used to assess geographical clustering. Standard deviation ellipse analysis was used to analyze the spatial and temporal trends of incidence.</p><p><strong>Results: </strong>The age-standardized incidence rate (ASIR) increased from 6.46/10⁵ in 2010 to 33.15/10⁵ in 2020, showing a nearly five-fold increase. The ASIR of urban regions was highest, but the growth rates of suburban regions and rural regions were faster than that of urban regions, and the regional disparity was gradually narrowing. The spatial distribution of thyroid cancer incidence has significant spatial heterogeneity and clustering. The hotspots clustered in the urban regions, Panyu and Nansha districts in the south, Huadu district in the north, and Zengcheng district in the east. The spatiotemporal evolution trends showed that since 2010, the incidence rate first migrated to the south-west, and then migrated to the north-east from 2015.</p><p><strong>Conclusions: </strong>Significant heterogeneity and clustering were seen in the spatial distribution of the thyroid cancer incidence rate in Guangzhou, and the regional disparity decreased. The direction of evolution consistent with Guangzhou's \"Southern Expansion, Northern Enhancement, Eastern Advancement, Western Integration and Central Revitalization\" spatial development policy.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}